Activating IGFLR1 to Promote Melanoma Cell Apoptosis

Kehan Ren

2022

Abstract

Purpose: Melanoma is one of the most common types of cancer with a high incidence rate. Surgical resection therapy is difficult to be applied to patients with extensive metastasis. Previous studies have reported that IGFL3 promotes the activation of CD4+ T cell and secretion of IFN-γ through the transmembrane protein IGFLR1, and IFN-γ inhibits tumor growth by inducing apoptosis of cancer cells. Activating IGFLR1 will upregulate the release of IFN-γ and promote cancer cell apoptosis. This paper investigates the effect of activation of IGFLR1 using IGFL1 recombinant protein on anti-melanoma treatment in both in vitro and in vivo conditions. In this work, eight possible outcomes of the experiments are discussed respectively. Different results will indicate whether or not IGFLR1 activation has a therapeutic effect on the anti-cancer treatment and provide critical information for the future clinical trial of IGFLR1 activation therapy.

Paper Citation

in Harvard Style

Ren K. (2022). Activating IGFLR1 to Promote Melanoma Cell Apoptosis. In Proceedings of the 4th International Conference on Biomedical Engineering and Bioinformatics - Volume 1: ICBEB, ISBN 978-989-758-595-1, pages 883-888. DOI: 10.5220/0011312600003443

in Bibtex Style

@conference{icbeb22,
author={Kehan Ren},
title={Activating IGFLR1 to Promote Melanoma Cell Apoptosis},
booktitle={Proceedings of the 4th International Conference on Biomedical Engineering and Bioinformatics - Volume 1: ICBEB,},
year={2022},
pages={883-888},
publisher={SciTePress},
organization={INSTICC},
doi={10.5220/0011312600003443},
isbn={978-989-758-595-1},
}

in EndNote Style

TY - CONF

JO - Proceedings of the 4th International Conference on Biomedical Engineering and Bioinformatics - Volume 1: ICBEB,
TI - Activating IGFLR1 to Promote Melanoma Cell Apoptosis
SN - 978-989-758-595-1
AU - Ren K.
PY - 2022
SP - 883
EP - 888
DO - 10.5220/0011312600003443